BioNTech to Acquire Kite's Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD

Deal strengthens BioNTech’s cell therapy pipeline by accelerating individualized solid tumor Neoantigen TCR cell therapy research and development program and adding manufacturing footprint in North America Kite remains focused on rapid advancement of current CAR T-Cell therapies to reach more patients and further optimize therapeutic potential of cell therapy MAINZ,